This immunotherapy combination shrinks rare, neuroendocrine
According to a new research, there is a significant clinical
benefit for patients with high-grade neuroendocrine carcinoma, which is
the cancer of the neuroendocrine cells that often form tumours in the
lungs and along the digestive tract too.
Even though, this cancer is rare, about 12,000 people in the United States are diagnosed with it, every year. But, do you know that the general prevalence of the disease grew six-fold between 1973 and 2012? Patients with the high-grade, or rapidly growing, form have tend to have only few treatment options.
“We saw a benefit in patients with high-grade carcinoma, which is the population that really needs an effective treatment option,” said a Dr. These early results are really encouraging and intriguing. We found a clear difference in response to treatment between the high-grade and low-grade forms of this cancer type,” said the Dr.”So tumour biology makes a difference. We don`t yet know why, but we`ve opened another treatment arm of the trial to patients with just high-grade neuroendocrine carcinoma to see if we find the same response to the immunotherapy combination,” the Dr. added.
DART features an innovative ‘basket’ design which allows the testing of a single drug or drug combination in a variety of tumour types. DART, currently tests the immunotherapy combination of ipilimumab and nivolumab in patients with 37 types of rare cancers, which together make up almost a quarter of all cancers diagnosed worldwide.
Researchers enrolled 33 patients with neuroendocrine tumours. Of those 33 patients, 19 had high-grade disease. Most patients’ tumours were located in the gastrointestinal tract or the lungs. All patients received doses of ipilimumab every six weeks and doses of nivolumab every two weeks and continue on the treatment for as long as their bodies respond to the drugs. Results showed that 42 per cent of patients with the high-grade form of neuroendocrine carcinomas saw their tumours shrink partially or completely after treatment, while none of the low-grade patients did. For all the patients, 70 per cent saw their cancer spread within six months.
Patients survived a median of at least 11 months after treatment. Some patients are alive more than a year after treatment, and doctors continue to track their progress.”There’s a myth that you can’t successfully complete clinical trials in rare cancers. Researchers think it’s too hard to find patients. But DART shows us that we can run rare cancer trials, and enroll patients quickly and learn if therapies are effective in rare diseases,” he said.”We can also offer investigational drugs to patients’ right in their communities. They don’t necessarily need to travel to a cancer centre to get enrolled in a clinical trial.”
Even though, this cancer is rare, about 12,000 people in the United States are diagnosed with it, every year. But, do you know that the general prevalence of the disease grew six-fold between 1973 and 2012? Patients with the high-grade, or rapidly growing, form have tend to have only few treatment options.
“We saw a benefit in patients with high-grade carcinoma, which is the population that really needs an effective treatment option,” said a Dr. These early results are really encouraging and intriguing. We found a clear difference in response to treatment between the high-grade and low-grade forms of this cancer type,” said the Dr.”So tumour biology makes a difference. We don`t yet know why, but we`ve opened another treatment arm of the trial to patients with just high-grade neuroendocrine carcinoma to see if we find the same response to the immunotherapy combination,” the Dr. added.
DART features an innovative ‘basket’ design which allows the testing of a single drug or drug combination in a variety of tumour types. DART, currently tests the immunotherapy combination of ipilimumab and nivolumab in patients with 37 types of rare cancers, which together make up almost a quarter of all cancers diagnosed worldwide.
Researchers enrolled 33 patients with neuroendocrine tumours. Of those 33 patients, 19 had high-grade disease. Most patients’ tumours were located in the gastrointestinal tract or the lungs. All patients received doses of ipilimumab every six weeks and doses of nivolumab every two weeks and continue on the treatment for as long as their bodies respond to the drugs. Results showed that 42 per cent of patients with the high-grade form of neuroendocrine carcinomas saw their tumours shrink partially or completely after treatment, while none of the low-grade patients did. For all the patients, 70 per cent saw their cancer spread within six months.
Patients survived a median of at least 11 months after treatment. Some patients are alive more than a year after treatment, and doctors continue to track their progress.”There’s a myth that you can’t successfully complete clinical trials in rare cancers. Researchers think it’s too hard to find patients. But DART shows us that we can run rare cancer trials, and enroll patients quickly and learn if therapies are effective in rare diseases,” he said.”We can also offer investigational drugs to patients’ right in their communities. They don’t necessarily need to travel to a cancer centre to get enrolled in a clinical trial.”
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE
HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
PS-
THOSE INTERESTED IN
RECIPES ARE FREE TO VIEW MY BLOG-
https://gseasyrecipes.blogspot.com/
FOR INFO ABOUT KNEE
REPLACEMENT, YOU CAN VIEW MY BLOG-
https:// kneereplacement-stickclub.blogspot.com/
FOR CROCHET DESIGNS https://gscrochetdesigns.blogspot.com
Labels: carcinoma, combination, digestive tract, high grade, Immunotherapy, Ipilimumab, lungs, neuroendocrine, Nivolumab, rare diseases, shrinks, tumours
posted by G S Iyer at 9:53 AM
0 Comments:
Post a Comment
<< Home